share_log

Truist Securities Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $50

Benzinga ·  Dec 22, 2023 10:02

Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and raises the price target from $48 to $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment